Is an OB (obstetric) formulation of midazolam used for intranasal administration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Intranasal Midazolam Formulation

No, you do not use an "OB formulation" for intranasal midazolam—there is no such thing as an obstetric formulation of midazolam for intranasal use. The term "OB formulation" is not a recognized pharmaceutical designation for midazolam in any route of administration.

What Formulation to Use for Intranasal Administration

For intranasal midazolam administration, use either the FDA-approved intranasal formulation (Nayzilam) or the standard intravenous formulation administered off-label via the intranasal route. 1, 2

FDA-Approved Intranasal Formulation

  • Nayzilam (midazolam nasal spray) is the FDA-approved intranasal formulation specifically designed for treating seizure clusters, approved in 2019 as the first nasally administered formulation for this indication. 1, 2
  • This formulation is optimized for intranasal delivery with appropriate concentration and delivery device. 2

Off-Label Use of IV Formulation

  • The standard intravenous midazolam formulation can be administered intranasally off-label, which has been extensively studied and used in clinical practice, particularly for acute seizure management. 3, 4, 5
  • The typical dose is 0.2 mg/kg administered equally in both nostrils for seizure control. 4, 5
  • This approach uses the water-soluble IV formulation (pH 3) that midazolam is available in, which allows for mucosal absorption. 6, 3

Clinical Efficacy and Safety

  • Intranasal midazolam 0.2 mg/kg is as effective as intravenous diazepam 0.5 mg/kg for controlling acute seizures, especially in children with febrile or afebrile seizures. 3
  • The mean time to seizure control with intranasal midazolam is approximately 3.2-3.6 minutes (not counting IV line insertion time for comparison drugs). 4, 5
  • Serious side effects like respiratory depression occur in only about 1% of cases, with local mucosal irritation occurring in less than one-third of cases. 3
  • No significant differences in oxygen saturation or heart rate have been observed compared to intravenous diazepam. 4

Common Pitfall to Avoid

Do not confuse terminology or create non-existent formulation names. There is no "OB formulation" of midazolam. If you need intranasal midazolam, use either the FDA-approved nasal spray (Nayzilam) or the standard IV formulation administered intranasally at 0.2 mg/kg. 3, 4, 1, 5, 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.